A Phase II, Open-label, Dose Escalation and Safety Study of Human Spinal Cord derived Neural Stem Cell Transplantation for the treatment of Amyotrophic Lateral Sclerosis
Phase of Trial: Phase II
Latest Information Update: 27 Jan 2016
At a glance
- Drugs NSI 566 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Neuralstem
- 27 Jan 2016 According to a Neuralstem media release, data from this study was presented at the Phacilitate Cell & Gene Therapy World Conference, Washington D.C.
- 29 Sep 2015 Results presented for 9 month phase II and combined phase I and phase II data presented at the American Neurological Association Annual Meeting.
- 24 Sep 2015 Results will be presented at the American Neurological Association Annual Meeting in Chicago, according to a Neuralstem media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History